FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
Arndt Vogel(Medizinische Hochschule Hannover), Vaibhav Sahai(University of Michigan), Antoine Hollebecque(Institut Gustave Roussy), Gina M. Vaccaro(Providence Portland Medical Center), Davide Melisi(University of Verona), Raed Moh’d Taiseer Al-Rajabi(The University of Kansas Cancer Center), Andrew Scott Paulson(Baylor University Medical Center), Mitesh J. Borad(Mayo Clinic in Arizona), David Gallinson(Morristown Medical Center), Adrian Murphy(Johns Hopkins University), Do‐Youn Oh(Seoul National University Hospital), Efrat Dotan(Fox Chase Cancer Center), Daniel V.T. Catenacci(University of Chicago), Eric Van Cutsem(KU Leuven), Christine Lihou(Incyte (United States)), Hui‐Ling Zhen(Incyte (United States)), Luis Féliz(Incyte (United States)), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center)
Cited by 59Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis